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Background: Hypoxia inducible factor 1α (HIF-1α) is a stress-responsive transcription factor to hypoxia and its
expression is correlated to tumor progression and angiogenesis. Several single nucleotide polymorphisms (SNPs) of
HIF-1α gene in the oxygen-dependent degradation (ODD) domain was reportedly associated with increased HIF-1α
activity.
Results: In this study, we focused on the relationship between SNP 1772 C > T (rs11549465) of HIF-1α gene and its
breast cancer risk, as well as its correlation with HIF-1α expression and tumor angiogenesis. Ninety six breast cancer
patients and 120 age-matched controls were enrolled. We found that 1772 T allele of HIF-1α gene was associated
with increased breast cancer risk (adjusted OR = 14.51; 95% CI: 6.74-31.24). This SNP was not associated with
clinicopathologic features of angiogenesis such as VEGF activity and the micro-vessel density and survival of
breast cancer patients.
Conclusion: Taken together, the 1772 C > T of HIF-1α gene is a potential biomarker for breast cancer susceptibility.
Keywords: HIF-1α, SNPs, Breast cancer, Association study, SurvivalBackground
Single nucleotide polymorphisms (SNPs), the most com-
mon variants in human genome [1], are popular bio-
markers for disease/cancer prediction and therapeutic
evaluation [2-8]. Most SNPs have been reported to be as-
sociated with breast cancer [9-11], however, other SNPs
are still potential to be associated with breast cancer.
Tumor hypoxia is common in tumorigenesis. Hypoxia
inducible factor-1 (HIF-1) is a crucial transcription fac-
tor in cellular response to tumor hypoxia and is consid-
ered as an adverse prognostic factor in breast cancers
[12-14]. Additionally, the HIF-1α isoform is the oxygen-
regulated component that controls HIF-1 activity [15]. The
degradation of HIF-1α depends on prolyl hydroxylation.
Under normoxic status, oxygen-dependent prolyl hydro-
xylases [16,17] may hydroxylate the HIF-1α on proline* Correspondence: shlin@kmu.edu.tw; changhw@kmu.edu.tw
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unless otherwise stated.residues 402 and 564 located in the oxygen-sensitive deg-
radation domain (ODD, encoded by codons 401–603) of
HIF-1α. In contrast, degradation of HIF-1α is suppressed
under hypoxic status. Therefore, the SNPs located at sev-
eral proline residues of HIF-1α gene in breast cancer asso-
ciation are potential to modulate the HIF-1α activity.
Recent studies demonstrated that another SNP located
in ODD of HIF-1α, 1772 C > T (rs11549465), may lead to
an amino acid change from proline 582 to serine (P582S)
and are reportedly associated with renal [18,19], head and
neck [20], prostate [21], lung [22], and pancreatic [23]
cancers. Meta-analysis from 34 case–control studies also
reported that SNP 1772 C > T (P582S) of HIF-1α gene is
significantly associated with breast cancer risk in many
countries [24]. However, the association of SNP 1772 C >
T (rs11549465) of the HIF-1α gene to breast cancer re-
mains unclear in a Taiwanese population.
The purpose of this study is to investigate the associ-
ation between SNP 1772 C > T of the HIF-1α gene in
breast cancer patients and healthy control subjects. Fur-
thermore, HIF-1 has been reported to transactivate many
oxygen responsive genes such as vascular endothelial
growth factor (VEGF) [25]. Therefore, the relationshipsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and the clinicopathologic characteristics, the immuno-
staining expression levels of HIF-1α and VEGF, and
clinical outcomes of breast cancer are also addressed in
this study.
Methods and materials
Patient characteristics and control subjects
Between 1991 and 2001, a total of 96 randomly-selected
female patients with breast cancer at Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan, were enrolled in
this study. All patients underwent a standard modified
radical mastectomy. Ninety-four patients (94/96, 98%)
received adjuvant systemic chemotherapy with 6 cycles
of 5-fluorourcil, doxorubicin and cyclophosphamide. After
completion of chemotherapy, all patients received hor-
mone therapy with tamoxifen and 92 patients (92/96, 96%)
received radiation therapy. The principle of treatment was
followed as described previously [26]. We collected clinical
data including clinical stage, treatment outcomes and
follow-up status. Controls were recruited from 120 healthy
female without a history of cancer and matched to the
breast cancer patients by sex and age.
DNA extraction and PCR-RFLP
Genomic DNA was isolated from paraffin-embedded
tumor tissues of surgical specimens and peripheral blood
of 120 normal controls as described [27,28]. The sequence
of primers for HIF-1α is as follows: forward 5′-AGGACA
CAGATTTAGACTTGG-3′ and reverse 5′-GGAATACT
GTAACTGTGCTTTG-3′. PCR reaction mixture (10 μl)
contained 1 μl of 10× PCR buffer, 0.3 μl of 50 mM MgCl2,
0.2 μl of 10 mM dNTP each, 0.6 μl DMSO, 0.14 μl of Taq
enzyme, 0.12 μl of 350 μg/ml primers mix (1:1), 2 μl DNA
extracts and 5.64 μl distilled water. PCR was performed
with the following protocol: 94°C (1 min); 4 cycles of 94°C
(15 s), 64°C (15 s), 70°C (8 s); 4 cycles of 94°C (15 s), 61°CTable 1 HIF-1α 1772 C > T genotype and allele frequencies in
Parameters Breast cancer patients Control subjects p
Age 46.5 ± 9.9 (19–73) 44.6 ± 11.5 (21–77) 0
CC (%) 53 (55%) 116 (97%)
CT (%) 21 (22%) 0 (0%)
TT (%) 22 (23%) 4 (3%) <
CT/CC (%) 74 (77%) 116 (97%)
TT (%) 22 (23%) 4 (3%) <
CC (%) 53 (55%) 116 (97%)
CT/TT (%) 43 (45%) 4 (3%) <
C genotype (%) 127 (66%) 232 (97%)
T genotype (%) 65 (34%) 8 (3%) <
aComparisons were performed by Chi-Square test.
bAdjusted by age by conditional logistic regression analysis.
OR = odds ratio; CI = Confidence interval.(15 s), 70°C (8 s); 4 cycles of 94°C (15 s), 58°C (15 s), 70°C
(8 s); 60 cycles of 94°C for (15 s), 55°C (15 s), 70°C (8 s);
94°C (1 min) and 60°C (5 min). The available restriction
enzyme for HIF-1α 1772 C > T (rs11549465) was retrieved
from the SNP-RFLP freeware [29-31]. PCR products were
digested with the Hph I restriction enzyme (NEB) at 37°C
for overnight and then they were subjected to 3% agarose
electrophoresis and stained with SYBR Safe™ DNA gel
stain (Invitrogen) for visualization of the PCR-restriction
fragment length polymorphism (PCR-RFLP) patterns.
Sequencing
Typical patterns of genotyping by PCR-RFLP have con-
firmed by sequencing. DNA amplicon from PCR reac-
tion was purified using a MiniElute PCR purification kit
(Qiagen) [28] for commercial sequencing.
Immunohistochemical analyses of HIF-1α and VEGF proteins
Streptoavidin-biotin based immunohistochemical stain-
ing (IHC) was performed to detect HIF-1α and VEGF
protein levels as previously described [32]. Immunoreactiv-
ity of HIF-1α was located in both nuclei and cytoplasm.
Using a semiquantitative scale described previously [33],
the HIF-1α expression were classified as follows: 1+,
nuclear staining in less than 1% of cells; 2+, nuclear stain-
ing in 1-10% of cells and/or with weak cytoplasmic stain-
ing; 3+, nuclear staining in 10-50% of cells and/or with
distinct cytoplasmic staining; 4+, nuclear staining in more
than 50% of cells and/or with strong cytoplasmic staining.
For further analysis, we defined two groups of low and high
HIF-1α expression: 1+ or 2+ staining pattern regarded as
low expression, and 3+ or 4+ staining pattern as high ex-
pression. VEGF expression was assessed according to the
intensity of cytoplasmic staining as described previously
[32]. VEGF expression was detected tumor cells in a dis-
tinct and strongly cytoplasmic staining. VEGF staining was
defined as four grades as follows: no staining, weak,breast cancer patients and control subjects
valuea Crude OR Adjusted ORb p value 95% CI
.224
1.00 1.00
0.001 12.04 11.33 <0.001 3.70-34.72
1.00 1.00
0.001 8.62 8.31 <0.001 2.74-25.25
1.00 1.00
0.001 23.53 23.23 <0.001 7.92-68.09
1.00 1.00
0.001 14.84 14.51 <0.001 6.74-31.24
Figure 1 PCR-RFLP genotyping and sequencing of SNP 1772 C > T of HIF-1α gene. (A) PCR-RFLP genotyping of SNP 1772 C > T of HIF-1α
gene (76 bp, C-allele; 153 bp, T-allele) in formalin-fixed, paraffin-embedded breast cancer tissues. (B) Sequence chromatograms of PCR-RFLP
product contained SNP 1772 C > T of HIF-1α gene. Arrow indicated location of 1772 C > T.
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strong cytoplasmic staining was defined as high VEGF
and negative or weak cytoplasmic staining was defined
as low VEGF expression.Immunohistochemical analysis for microvessel detection
Microvessel density (MVD) represents tumor angiogen-
esis by using immunostaining of endothelial cells with
monocloncal antibody, recognizing the CD31 endothelial
glycoprotein. Each slide was scanned at low magnifica-
tion (× 100) to identify the four areas of high density of
microvessels (hotspots). The number of stained vessels per
in each hotspot was counted at high power fields (× 400).
Any stained endothelia cell was considered as a countable
single microvessel. Large vessels with thick muscular walls
were excluded. MVD was classified as either low (≦35.0)
or high (>35.0/high power field (HPF)); 35.0 was the me-
dian value.Figure 2 Expression of (A) HIF-1α, (B) VEGF and (C) CD34 for microve
breast cancer.Statistical analysis
Statistical significance was evaluated by the chi-square
test and Fisher exact test. Overall survival curves were
analyzed by the Kaplan-Meier method, and differences
between the curves were analyzed by log-rank test. The
p values smaller than 0.05 are regarded as significance.Results
In Table 1, the mean age of the breast cancer patients was
46.5 years (range 19–73 years), and this was 44.6 years for
controls (range 21–77 years). There was no significant dif-
ference between breast cancer patients and controls in age
(p = 0. 22).
In Figure 1A, RFLP results demonstrated that CC geno-
type yielded one band (76 base pairs), CT genotype yielded
two bands (76 bp, C-allele; 153 bp, T allele) and TT geno-
type yielded one band (153 bp). The corresponding geno-
types of homozygous and heterozygous patterns fromssel density (200×) of a 34 year-old female patient with T2N1M0
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(Figure 1B).
Based on PCR-RFLP analysis, the genotype distribu-
tion of control group was 116 CC (97%), 0 CT (0%) and
4 TT (3%). In contrast, the genotype distributions of
breast cancer patients were 53 CC (55%), 21 CT (22%),
and 22 TT (23%). The genotype distribution in breast
cancer patients differed significantly from that of con-
trols (p < 0.001). The allele frequencies in controls and
cancer patients were 232 C (97%)/8 T (3%) and 127 C
(66%)/65 T (34%), respectively. The T-allele distribution
in breast cancer patients differed significantly from that
of controls (p < 0.001, adjusted OR = 14.51).
Immunoreactivity of HIF-1α was distributed in both
nuclei and cytoplasm (Figure 2A). VEGF expression was
measured by its cytoplasmic staining (Figure 2B). Micro-
vessel density (MVD) representing tumor angiogenesis
was measured by immunostaining of CD31 endothelial
glycoprotein (Figure 2C).
When connecting the results of these stainings with HIF-
1α genotypes with clinicopathological analysis (Table 2),
there were no significant correlation between 1772 C >TTable 2 Clinicopathologic characteristics, clinical
outcomes in breast cancer patients with different
HIF-1α 1772 C > T genotypes
Genotype CC (%) CT (%) TT (%) p value
Case number 53 (55%) 21 (22%) 22 (23%)
Age 0.117a
Mean ± SD (years) 46.5 ± 9.7 43.1 ± 10.3 49.4 ± 9.6
Range (years) 27 ~ 68 19 ~ 62 31 ~ 73
Laterality 0.463b
Left 26 (52%) 10 (20%) 14 (28%)
Right 27 (58%) 11 (24%) 8 (17%)
T-stage 0.303b
T1 or T2 35 (53%) 13 (20%) 18 (27%)
T3 or T4 18 (60%) 8 (27%) 4 (13%)
N-stage 0.936b
Node negative 14 (58%) 5 (21%) 5 (21%)
Node positive 39 (54%) 16 (22%) 17 (24%)
HIF-1α expression 0.311b
Low 34 (51%) 15 (22%) 18 (27%)
High 19 (66%) 6 (21%) 4 (14%)
VEGF expression 0.375b
Low 18 (62%) 7 (24%) 4 (14%)
High 35 (52%) 14 (21%) 18 (27%)
Microvessel density 0.211b
Low 32 (63%) 8 (16%) 11 (22%)
High 21 (47%) 13 (29%) 11 (24%)
aby ANOVA test.
bby Chi-Square test.genotypes (CC, CT and TT) of HIF-1α gene and age (p =
0.117), T-stage (p = 0.303), N-stage (p = 0.936), local recur-
rence (p = 0.817), distant metastasis (p = 0.572), HIF-1α
expression (p = 0.311), VEGF expression (p = 0.375) and
microvessel density (p = 0.211).
In Table 3, the multi-variable analyses in the determin-
ation of risk factors of disease-free survival and overall
survival indicated that T-stage (Exp. (B) = 4.7270, p <
0.001) and microvessel density (Exp. (B) = 2.6082, p < 0.05)
were the most influential factors (Table 3). However, the
SNP 1772 C > T genotypes of HIF-1α gene were not corre-
lated with the disease-free survival (p = 0.35, Cox regres-
sion) and overall survival (p = 0.59, Cox regression) by
multi-variable analyses. Similarly, Kaplan-Meier analysis
(Figures 3A and 3B) also showed a nonsignificant impact
of 1772 C > T genotypes of HIF-1α gene on disease-free
survival (p = 0.820, Log-Rank test) and overall survival
curves (p = 0.963, Log-Rank test), respectively.
Discussion
The SNP 1772 C > T of HIF-1α gene chosen in current
study are located within ODD of the HIF-1α. We found
that T allele of the SNP 1772 C > T (P582S) of HIF-1α
gene was significantly higher in 96 breast cancer patients
than in 120 controls. In contrast, the association results
of SNP 1772 C > T of HIF-1α gene with different kinds
of cancers were not consistent in literature review. ForTable 3 Multivariate analysis of the risk factors on
disease-free and overall survival in the 96 breast cancer
patients




Age 0.0253 0.1280 0.9622 0.9156 ~1.0112
1772 C > T genotype 0.2715 0.3527 1.2871 0.7559 ~2.1913
T-stage 0.4033 0.0001 4.7270 2.1445 ~10.4196
N-stage 0.5291 0.9816 1.0122 0.3588 ~2.8554
Microvessel density 0.4877 0.0493 2.6082 1.0028 ~6.7837
VEGF expression 0.5858 0.2901 1.8584 0.5895 ~5.8587
HIF-1α expression 0.4346 0.0732 2.1784 0.9294 ~5.1059
Overall survival time
Age 0.022 0.4883 0.9846 0.9422 ~1.0288
1772 C > T genotype 0.300 0.5908 0.8508 0.4722 ~1.5330
T-stage 0.446 0.0017 4.0350 1.6850 ~9.6624
N-stage 0.589 0.8594 1.1099 0.3502 ~3.5181
Microvessel density 0.646 0.0052 6.0924 1.7175 ~21.6115
VEGF expression 0.610 0.9791 0.9841 0.2979 ~3.2517
HIF-1α expression 0.481 0.3225 1.6094 0.6269 ~4.1315
aby Cox regression. SE, standard error; Exp. (B), exponent (B); CI, confidence interval.
bBold numbers indicate significance.
Figure 3 Kaplan-Meier disease-free and overall survival curves in breast cancer patients with different genotypes (1772 C > T) of
HIF-1α gene. (A) Disease-free survival. (B) overall survival curves.
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tected in several cancers [18-21,23] but it was absent for
colorectal [34], and cervical [35] cancers.
Within ODD of the HIF-1α, proline residues 402 and
564 were reported to independently determine tightly
binding to the von Hippel-Lindau (VHL) protein for
HIF-1α ubiquitination and degradation under nonhy-
poxia condition [17,36-39]. In current study, however,
the proline residue 582 located within ODD of the HIF-
1α, i.e., the SNP 1772 C > T, was unable to interfere the
binding of HIF-1α with VHL and to impair HIF-1α pro-
lyl hydroxylation [40]. Similarly, the genotypes of SNP
1772 C > T of HIF-1α gene did not show significant dif-
ference between low and high HIF-1α levels in terms of
immunostaining (Table 2). Other study [41] found that
the HIF-1α overexpressed in immunostaining measure-
ment for invasive breast cancer in the absence of 1772C > T transition of HIF-1α gene. Accordingly, the role of
SNP 1772 C > T of HIF-1α gene in its protein expression
level is not clear. In future, the examination of more ex-
pression patterns of HIF-1α protein in these patients
may clearly investigate this relationship.
Furthermore, the genotypes of SNP 1772 C > T of
HIF-1α gene are not significantly associated with clinico-
pathologic characteristics and clinical outcome of breast
cancer (Table 2) although SNP 1772 C > T of HIF-1α gene
confers significant association with breast cancer (Table 1).
Similar results were reported in prostate cancer study
[21]. Therefore, the SNP 1772 C > T of HIF-1α gene is a
good predictor for breast cancer risk but may be a poor
clinicopathologic-associated factor.
The relationship between expression levels of HIF-1α
and survival of breast cancer patients has been investi-
gated. For example, high levels of HIF-1α were reportedly
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and disease-free survival (p = 0.110) [42]. Similarly, we
found that HIF-1α expression shows the association
with disease-free survival (p = 0.0732) but weak association
with overall survival (p = 0.3225) (Table 3). These results
suggest that expression levels of HIF-1α may be the poten-
tial risk factor for survival prediction of breast cancer.
The phenomena mentioned above may be partly ex-
plained by the multigene theory for carcinogenesis [43].
Furthermore, many SNPs may be associated with breast
cancer. Although only single SNP was examined in our
study, the SNP-SNP interaction [9,44-48] tumor may play
a joint effect to associate with cancer and it is warranted
for further investigation for multiple SNPs in breast can-
cer association.
Conclusion
Taken together, SNP 1772 C > T (P582S) of HIF-1α gene
confers significant association with breast cancer risk but
it show no association with the clinicopathologic features
and survival of breast cancer patients.
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